8QN5
M. tuberculosis salicylate synthase MbtI in complex with methyl-AMT (new crystal form)
これはPDB形式変換不可エントリーです。
8QN5 の概要
| エントリーDOI | 10.2210/pdb8qn5/pdb |
| 分子名称 | Salicylate synthase, 3-{[(1Z)-1-carboxyprop-1-en-1-yl]oxy}-2-hydroxybenzoic acid, GLYCEROL, ... (6 entities in total) |
| 機能のキーワード | salicylate, isochorismate, chorismate, mycobactins, lyase |
| 由来する生物種 | Mycobacterium tuberculosis H37Rv |
| タンパク質・核酸の鎖数 | 4 |
| 化学式量合計 | 197643.09 |
| 構造登録者 | Mori, M.,Villa, S.,Meneghetti, M.,Bellinzoni, M. (登録日: 2023-09-25, 公開日: 2023-11-15, 最終更新日: 2023-12-06) |
| 主引用文献 | Mori, M.,Villa, S.,Chiarelli, L.R.,Meneghetti, F.,Bellinzoni, M. Structural Study of a New MbtI-Inhibitor Complex: Towards an Optimized Model for Structure-Based Drug Discovery. Pharmaceuticals, 16:-, 2023 Cited by PubMed Abstract: MbtI from () is a Mg-dependent salicylate synthase, belonging to the chorismate-utilizing enzyme (CUE) family. As a fundamental player in iron acquisition, MbtI promotes the survival and pathogenicity of in the infected host. Hence, it has emerged in the last decade as an innovative, potential target for the anti-virulence therapy of tuberculosis. In this context, 5-phenylfuran-2-carboxylic acids have been identified as potent MbtI inhibitors. The first co-crystal structure of MbtI in complex with a member of this class was described in 2020, showing the enzyme adopting an open configuration. Due to the high mobility of the loop adjacent to the binding pocket, large portions of the amino acid chain were not defined in the electron density map, hindering computational efforts aimed at structure-driven ligand optimization. Herein, we report a new, high-resolution co-crystal structure of MbtI with a furan-based derivative, in which the closed configuration of the enzyme allowed tracing the entirety of the active site pocket in the presence of the bound inhibitor. Moreover, we describe a new crystal structure of MbtI in open conformation and in complex with the known inhibitor methyl-AMT, suggesting that in vitro potency is not related to the observed enzyme conformation. These findings will prove fundamental to enhance the potency of this series via rational structure-based drug-design approaches. PubMed: 38004425DOI: 10.3390/ph16111559 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (1.544 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






